BridgeBio Pharma, Inc. (BBIO): what it filed
Regulatory filings for BridgeBio Pharma, Inc. (BBIO), each one linked back to the document it was parsed from, and each score stating the inputs it was built from.
Streams covered here: 5%+ stake filing (13d/g), material corporate event (8-k), planned insider sale (form 144).
Recent filings
2026-08-19 - Planned insider sale (Form 144) - score 87/100
value: $2,489,400 · approx sale date: 2026-08-19 · role: Director · seller: KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019
2026-08-18 - Planned insider sale (Form 144) - score 87/100
value: $2,794,552 · approx sale date: 2026-08-18 · role: Director · seller: NEIL KUMAR
2026-08-17 - Material corporate event (8-K) - score 70/100
items: Entry into material agreement / deal; Financial statements and exhibits; Other events
2026-08-17 - 5%+ stake filing (13D/G) - score 75/100
holder: KKR Genetic Disorder L.P. · intent: Activist stake change (13D/A) - position or intent updated - 4.2% of class · is amendment: Amendment
2026-08-17 - Planned insider sale (Form 144) - score 87/100
value: $1,717,070 · approx sale date: 2026-08-17 · role: Director · seller: RANDAL SCOTT
Being straight about what this is
Not advice. This page reports what a public filing says and links to it. It draws no conclusion from that.
Some scores are built on incomplete inputs. Where a filing does not publish every term the formula uses, the record carries inputs_complete: false and the score is still shown. The gap is reported, not filled in with a guess.
Refreshed once a night, and some publishers are slower by nature: congressional trades weekly, institutional holdings quarterly.
Names come from the filing. Where a person is named, that name is a required disclosure field in the public document, and the link above goes to it.
DataSignals Lab publishes data and research. Informational only, not investment advice, not an offer or solicitation. Every figure links back to the official filing so you can verify it yourself.